Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
NeuroSense received a Nasdaq notice for not meeting the $2.5M stockholders' equity requirement but continues trading under 'NRSN'. It has until Feb 5, 2024, to submit a compliance plan, with a possible extension to June 18, 2024. The company remains committed to advancing PrimeC, its ALS treatment, despite the notice.
Pipeline Moves: Advancement prospects plunge for Parkinson’s
Phase III trial for Parkinson's disease terminated, reducing DNL-151's LoA to 14%. LIB Therapeutics' lerodalcibep shows promise in HeFH, increasing LoA to 65%. AstraZeneca's MEDI-7352 completes Phase IIb for osteoarthritis pain, PTSR rises to 45%. Incyte's itacitinib completes Phase II for CRS, PTSR increases to 60%.
Related Clinical Trials:
Game-changing Alzheimer's drugs could drive a wave of new hope and investment opportunities
Recent breakthroughs in Alzheimer's treatment, notably lecanemab's FDA approval and donanemab's Phase 3 trial success, offer new hope for patients and investment opportunities. Despite challenges in access and infrastructure, these developments mark a significant step forward in combating Alzheimer's, promising better outcomes and reducing healthcare burdens.
Biotechnology Market is Expanding USD 3995.22 Billion
The global biotechnology market, valued at USD 1,224.31 billion in 2022, is projected to reach USD 3,995.22 billion by 2032, growing at a 12.5% CAGR. It drives innovation in healthcare, agriculture, and environmental sustainability, with bio-pharmacy leading through precision medicine, biologics, and immuno-oncology. Despite regulatory and IP challenges, opportunities in personalized medicine and rare diseases are expanding. Key players include Novartis, Roche, and Biogen.
Synapticure on Science: Clinical Trials for Sporadic ALS
The ALS drug development pipeline is rich with promising therapies targeting TDP-43 pathology, including Biogen’s BIIB-105, AbbVie/Calico’s ABBV-CLS-7262, Denali’s DNL-343, and QurAlis’ QRL-201. Trials range from Phase 1 to Phase 3, with completion dates extending to 2026. These therapies aim to slow ALS progression by addressing TDP-43 mislocalization and aggregation, a hallmark of ALS pathology. The article also highlights the importance of clinical trials in advancing ALS treatment and the potential for FDA approval of these therapies.
Related Clinical Trials:
US announces trial Medicare payment program for care providers of dementia patients
The U.S. government announced a trial payment program for dementia care coordination under Medicare, aiming to delay nursing home care. It includes personalized assessments, care plans, and 24/7 support. The pilot will test a per-patient per-month payment model, starting July 2024 for eight years, targeting 6.5 million Americans with dementia.
US announces 8-year-trial Medicare payment program for caretakers of dementia patients
The U.S. government announced a trial payment program for dementia care coordination under Medicare, offering personalized assessments, care plans, and 24/7 support. Aimed at delaying nursing home care, it includes a per-patient per-month payment model and access to clinical and non-clinical services. Applications open autumn 2023, with the trial running from July 2024 for eight years.
Drug donanemab seen as turning point in dementia fight
Donanemab, a new Alzheimer's drug, slows cognitive decline by clearing brain protein buildup, marking a treatment era. Trials show it slows disease progression by 20-30%, with significant side-effects. UK's NICE is assessing it for NHS use, highlighting the need for diagnostic and treatment infrastructure improvements.
Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year
Leqembi, the first FDA-approved Alzheimer's drug proven to slow disease progression, may soon be joined by Eli Lilly's donanemab. Both target amyloid protein in the brain, showing modest benefits in slowing cognitive decline. Despite safety concerns and high costs, they offer hope for early-stage Alzheimer's patients.
Polyunsaturated Fats and ALS Disease Progression, CAP-1002 Improves Motor Function in DMD, Lecanemab Granted Traditional Approval
Higher alpha-linolenic acid (ALA) levels linked to longer survival and slower ALS progression. CAP-1002 shows improved cardiac function in DMD patients over 2 years. FDA grants traditional approval to Eisai’s Alzheimer’s drug lecanemab, expanding access for the aging population.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath